KCM
Kynam Capital Management Portfolio holdings
AUM
$929M
This Quarter Return
-3.14%
1 Year Return
-7.66%
3 Year Return
+163.82%
5 Year Return
–
10 Year Return
–
AUM
$1.52B
AUM Growth
+$1.52B
(+17%)
Cap. Flow
+$295M
Cap. Flow
% of AUM
19.44%
Top 10 Holdings %
Top 10 Hldgs %
77.36%
Holding
31
New
5
Increased
13
Reduced
5
Closed
–
Top Buys
| 1 |
Vaxcyte
PCVX
|
$106M |
| 2 |
Celldex Therapeutics
CLDX
|
$40.6M |
| 3 |
Immunocore
IMCR
|
$36.2M |
| 4 |
Syndax Pharmaceuticals
SNDX
|
$35.4M |
| 5 |
enGene Holdings
ENGN
|
$21.7M |
Top Sells
| 1 |
Dynavax Technologies
DVAX
|
$22.6M |
| 2 |
Vera Therapeutics
VERA
|
$5.02M |
| 3 |
Natera
NTRA
|
$3.23M |
| 4 |
Protagonist Therapeutics
PTGX
|
$2.53M |
| 5 |
Cogent Biosciences
COGT
|
$1.05M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Relay Therapeutics
RLAY
$619M
| $4.12M | 0.24% |
+1,000,000
| New | +$4.12M |
|
27
Caribou Biosciences
CRBU
$174M
| $3.83M | 0.23% |
2,406,147
+50,000
| +2% | +$79.5K |
|
|
SLRN
28
DELISTED
ACELYRIN
SLRN
| $2.66M | 0.16% |
847,366
| – | – |
|
|
CLYM
29
Climb Bio, Inc. Common Stock
CLYM
$151M
| $985K | 0.06% |
+547,000
| New | +$985K |
|
30
SPDR S&P 500 ETF Trust
SPY
$658B
| – | – |
0
| – | – |
|
31
Vertex Pharmaceuticals
VRTX
$100B
| – | – |
0
| – | – |
|